Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 4 Results of the RESORCE trial[41]
Regorafenib (n = 379)Placebo (n = 194)HR, P-value
OS (M, 95%CI)10.6 (9.1-12.1)7.8 (6.3-8.8)HR 0.63 (95%CI 0.50-0.79) P < 0.0001
PFS (M, 95%CI)3.1 (2.8-4.1)10.6 (1.4-1.6)HR 0.46 (95%CI 0.37-0.56) P < 0.0001
TTP (M, 95%CI)3.2 (2.9-4.2)10.6 (1.4-1.6)HR 0.44 (95%CI 0.36-0.55) P < 0.0001
Objective response(investigator assessed, mRECIST)
CR2 (1%)0
PR38 (10%)8 (4%)
SD206 (54%)62 (32%)
PD86 (23%)108 (56%)
ORR40 (11%)8 (4%)P = 0.0047
DCR247 (65%)70 (36%)P < 0.0001